Literature DB >> 25657435

Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab.

Vasudha V Sardesai1, Vidyadhar R Sardesai2, Trupti D Agarwal2.   

Abstract

Systemic Lupus Erythematosus (SLE) is a multisystem disorder characterized by production of numerous autoantibodies, some of which have pathogenic consequences and result in considerable morbidity. Herein, we present a case of 48-year-old female with SLE having autoimmune hemolytic anemia, autoimmune thrombocytopenia, renal involvement, and recurrent flares of skin manifestations. She did not respond to the conventional therapy and was controlled and treated with Rituximab, a chimeric, monoclonal antiCD20 antibody, which specifically depletes B lymphocytes.

Entities:  

Keywords:  Rituximab; systemic lupus erythematous; thrombocytopenia

Year:  2015        PMID: 25657435      PMCID: PMC4318041          DOI: 10.4103/0019-5154.147874

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


  10 in total

1.  Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.

Authors:  M M Ward; E Pyun; S Studenski
Journal:  Arch Intern Med       Date:  1996-06-24

2.  The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders.

Authors:  Massimo Franchini; Dino Veneri; Giuseppe Lippi; Rachel Stenner
Journal:  Thromb Haemost       Date:  2006-08       Impact factor: 5.249

3.  Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.

Authors:  Hua Chen; Wenjie Zheng; Jinmei Su; Dong Xu; Qian Wang; Xiaomei Leng; Wen Zhang; Mengtao Li; Fulin Tang; Xuan Zhang; Xiaofeng Zeng; Yan Zhao; Fengchun Zhang
Journal:  Rheumatology (Oxford)       Date:  2011-05-13       Impact factor: 7.580

Review 4.  Drug insight: rituximab in renal disease and transplantation.

Authors:  Alan D Salama; Charles D Pusey
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

5.  Splenic radiation for corticosteroid-resistant immune thrombocytopenia.

Authors:  D C Calverley; G W Jones; J G Kelton
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

6.  Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades.

Authors:  K E Moss; Y Ioannou; S M Sultan; I Haq; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

7.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

8.  Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide.

Authors:  B A Roach; G J Hutchinson
Journal:  Arthritis Rheum       Date:  1993-05

9.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

10.  Dapsone for autoimmune thrombocytopenic purpura.

Authors:  B Godeau; E Oksenhendler; P Bierling
Journal:  Am J Hematol       Date:  1993-09       Impact factor: 10.047

  10 in total
  2 in total

1.  Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases.

Authors:  Wei Zhang; Fan Wang; Hong Wang; Bingzhu Hua; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

2.  Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Authors:  Fatma Alshaiki; Elaf Obaid; Abdulqader Almuallim; Rabab Taha; Hadeel El-Haddad; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2018-02-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.